Interesting that the proposed trial will utilise local PFS as...

Interesting that the proposed trial will utilise local PFS as the primary endpoint.

Sirtex were prevented by the FDA from doing this in the SIRFLOX trial. They found a significant delay in local progression of liver metastases when treated with local radiation, but no impact on overall PFS. We are still awaiting the OS data. As if stands oncologists are unlikely to change practice and implement an expensive therapy in first line unless an OS benefit is confirmed.

What is the significance of prolonged local PFS for pancreatic cancer? We have no idea. The OS data will be far more important in determining whether this therapy will get broad use. Without this there would need to be another significant benefit like pain control to justify the expense of the procedure. Still a good Ann today, just food for thought.